Boston Scientific Co. (NYSE:BSX) Shares Bought by Benjamin Edwards Inc.

Benjamin Edwards Inc. grew its holdings in Boston Scientific Co. (NYSE:BSX - Free Report) by 5,065.7% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 14,154 shares of the medical equipment provider's stock after buying an additional 13,880 shares during the quarter. Benjamin Edwards Inc.'s holdings in Boston Scientific were worth $1,186,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of BSX. Csenge Advisory Group boosted its position in Boston Scientific by 7.7% during the second quarter. Csenge Advisory Group now owns 3,872 shares of the medical equipment provider's stock worth $298,000 after purchasing an additional 278 shares in the last quarter. Opal Wealth Advisors LLC purchased a new position in shares of Boston Scientific during the 2nd quarter worth approximately $110,000. SG Americas Securities LLC raised its position in shares of Boston Scientific by 7.0% during the 2nd quarter. SG Americas Securities LLC now owns 230,661 shares of the medical equipment provider's stock worth $17,763,000 after purchasing an additional 15,125 shares during the last quarter. Ignite Planners LLC lifted its stake in Boston Scientific by 14.1% in the 2nd quarter. Ignite Planners LLC now owns 3,695 shares of the medical equipment provider's stock valued at $282,000 after buying an additional 458 shares in the last quarter. Finally, GSG Advisors LLC acquired a new stake in shares of Boston Scientific during the 2nd quarter worth about $358,000. Institutional investors and hedge funds own 89.07% of the company's stock.

Boston Scientific Stock Down 0.5 %

Shares of NYSE:BSX traded down $0.46 during trading on Friday, hitting $90.07. The company's stock had a trading volume of 3,302,016 shares, compared to its average volume of 4,982,464. The company has a market capitalization of $132.75 billion, a PE ratio of 74.44, a PEG ratio of 2.68 and a beta of 0.80. Boston Scientific Co. has a fifty-two week low of $54.52 and a fifty-two week high of $91.93. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.02 and a current ratio of 1.48. The stock's 50-day moving average price is $87.40 and its two-hundred day moving average price is $81.30.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its earnings results on Wednesday, October 23rd. The medical equipment provider reported $0.63 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.59 by $0.04. Boston Scientific had a return on equity of 17.23% and a net margin of 11.26%. The company had revenue of $4.21 billion for the quarter, compared to analyst estimates of $4.04 billion. During the same period in the prior year, the company posted $0.50 EPS. Boston Scientific's quarterly revenue was up 19.3% on a year-over-year basis. As a group, sell-side analysts expect that Boston Scientific Co. will post 2.46 EPS for the current year.

Insider Buying and Selling at Boston Scientific

In related news, Director Edward J. Ludwig sold 4,877 shares of the company's stock in a transaction that occurred on Thursday, November 21st. The stock was sold at an average price of $91.63, for a total transaction of $446,879.51. Following the sale, the director now directly owns 39,398 shares of the company's stock, valued at approximately $3,610,038.74. This represents a 11.02 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Wendy Carruthers sold 6,983 shares of Boston Scientific stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $83.86, for a total transaction of $585,594.38. Following the completion of the transaction, the executive vice president now directly owns 34,748 shares of the company's stock, valued at approximately $2,913,967.28. This represents a 16.73 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 328,157 shares of company stock worth $27,957,676 in the last ninety days. 0.50% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several equities analysts recently commented on BSX shares. BTIG Research upped their price target on shares of Boston Scientific from $84.00 to $93.00 and gave the stock a "buy" rating in a research report on Monday, October 14th. Royal Bank of Canada increased their target price on Boston Scientific from $95.00 to $98.00 and gave the stock an "outperform" rating in a research report on Thursday, October 24th. Mizuho boosted their price target on Boston Scientific from $100.00 to $110.00 and gave the company an "outperform" rating in a research report on Thursday, October 24th. Morgan Stanley raised their price objective on Boston Scientific from $92.00 to $100.00 and gave the stock an "overweight" rating in a report on Thursday, October 24th. Finally, StockNews.com lowered Boston Scientific from a "buy" rating to a "hold" rating in a research note on Monday, November 4th. Four research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Boston Scientific has a consensus rating of "Moderate Buy" and a consensus target price of $93.39.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.